These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 21126271

  • 1. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
    Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kröger N, Zander AR.
    Mycoses; 2011 Jan; 54 Suppl 1():39-44. PubMed ID: 21126271
    [Abstract] [Full Text] [Related]

  • 2. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY.
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [Abstract] [Full Text] [Related]

  • 3. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R.
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [Abstract] [Full Text] [Related]

  • 4. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF, Aoun M, Caillot D, Sable C, Caspofungin Combination Therapy Study Group.
    Cancer; 2006 Dec 15; 107(12):2888-97. PubMed ID: 17103444
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A, Korb V, Guillemain R, Caruba T, Boussaud V, Billaud E, Prognon P, Begué D, Sabatier B.
    J Clin Pharm Ther; 2010 Feb 15; 35(1):49-53. PubMed ID: 20175811
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
    Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II.
    Cancer; 2003 Jul 15; 98(2):292-9. PubMed ID: 12872348
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
    Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ, Caspofungin Salvage Aspergillosis Study Group.
    Clin Infect Dis; 2004 Dec 01; 39(11):1563-71. PubMed ID: 15578352
    [Abstract] [Full Text] [Related]

  • 8. Combination antifungal therapy for invasive aspergillosis.
    Marr KA, Boeckh M, Carter RA, Kim HW, Corey L.
    Clin Infect Dis; 2004 Sep 15; 39(6):797-802. PubMed ID: 15472810
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study.
    León-Gil C, Ubeda-Iglesias A, Loza-Vázquez A, de la Torre MV, Raurich-Puigdevall JM, Alvarez-Sánchez B, Ortiz-Leyva C, Domínguez-Roldán JM, Socías-Crespi L, Garnacho-Montero J, ProCAS Study Group.
    Rev Esp Quimioter; 2012 Dec 15; 25(4):274-82. PubMed ID: 23303260
    [Abstract] [Full Text] [Related]

  • 10. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A.
    Morrissey CO, Slavin MA, O'Reilly MA, Daffy JR, Seymour JF, Schwarer AP, Szer J.
    Mycoses; 2007 Dec 15; 50 Suppl 1():24-37. PubMed ID: 17394607
    [Abstract] [Full Text] [Related]

  • 11. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
    Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA.
    J Infect; 2005 Apr 15; 50(3):196-205. PubMed ID: 15780413
    [Abstract] [Full Text] [Related]

  • 12. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
    Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR.
    Clin Infect Dis; 2007 Jan 01; 44(1):2-12. PubMed ID: 17143808
    [Abstract] [Full Text] [Related]

  • 13. Caspofungin therapy in immunocompromised children and neonates.
    Somer A, Törün SH, Salman N.
    Expert Rev Anti Infect Ther; 2011 Mar 01; 9(3):347-55. PubMed ID: 21417874
    [Abstract] [Full Text] [Related]

  • 14. [Addressing the "Hot Spots" in the management of invasive aspergillosis].
    Kontoyiannis D.
    Med Mal Infect; 2007 Mar 01; 37 Suppl 2():9-11. PubMed ID: 17933659
    [Abstract] [Full Text] [Related]

  • 15. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
    Jarque I, Tormo M, Bello JL, Rovira M, Batlle M, Julià A, Tabares S, Rivas C, Fernández-Sevilla A, García-Boyero R, Debén G, González-Campos J, Capote FJ, Sanz MA, Spanish Pethema Group.
    Med Mycol; 2013 Feb 01; 51(2):150-4. PubMed ID: 22712457
    [Abstract] [Full Text] [Related]

  • 16. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao CC, Seibel N, Laws HJ, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL.
    Pediatrics; 2009 Mar 01; 123(3):877-84. PubMed ID: 19255017
    [Abstract] [Full Text] [Related]

  • 17. Caspofungin for treatment of invasive aspergillus infections.
    Heinz WJ, Einsele H.
    Mycoses; 2008 Mar 01; 51 Suppl 1():47-57. PubMed ID: 18471161
    [Abstract] [Full Text] [Related]

  • 18. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
    Agarwal MB, Rathi SA, Ratho N, Subramanian R.
    J Assoc Physicians India; 2006 Dec 01; 54():943-8. PubMed ID: 17334012
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of caspofungin in solid organ transplant recipients.
    Petrovic J, Ngai A, Bradshaw S, Williams-Diaz A, Taylor A, Sable C, Vuocolo S, Kartsonis N.
    Transplant Proc; 2007 Dec 01; 39(10):3117-20. PubMed ID: 18089335
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW, Raad II, Maertens JA, Hachem RY, Saah AJ, Sable CA, Chodakewitz JA, Severino ME, Saddier P, Berman RS, Ryan DM, Dinubile MJ, Patterson TF, Denning DW, Walsh TJ.
    Eur J Clin Microbiol Infect Dis; 2010 Nov 01; 29(11):1387-94. PubMed ID: 20703506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.